Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Dividend History CRDF

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Dividend Analytics CRDF

Max Ratio

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Forward Annual Dividend Yield
Consecutive Years
Forward Annual Dividend – USD
Consistent Years
Dividend CAGR 3Y
Continuous Dividends
Dividend CAGR 5Y
Payout Ratio TTM
Dividend CAGR 10Y
Ex Dividend Date

Cardiff Oncology Inc

CRDF
Current price
3.65 USD -0.06 USD (-1.62%)
Last closed 3.66 USD
ISIN US14147L1089
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 243 484 800 USD
Yield for 12 month +67.43 %
1Y
3Y
5Y
10Y
15Y
CRDF
21.11.2021 - 28.11.2021

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer. The company also focuses on the clinical program in indications, such as investigator-initiated ongoing or planned trials in metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, and triple negative breast cancer; CRDF-004, a Phase 2 open-label randomized multi-center clinical trial of onvansertib in combination with SoC FOLFIRI and bevacizumab or SoC FOLFOX and bevacizumab for the first-line treatment of patients with RAS-mutated mCRC; TROV-054, a Phase 1b/2 open-label multi-center clinical trial of onvansertib in combination with SoC FOLFIRI and bevacizumab for the second-line treatment of patients with KRAS-mutated mCRC; and CRDF-001, a Phase 2 open-label multi-center clinical trial of onvansertib in combination with nanoliposomal irinotecan leucovorin, and fluorouracil for second line treatment of patients with mPDAC. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was founded in 1999 and is headquartered in San Diego, California. Address: 11055 Flintkote Avenue, San Diego, CA, United States, 92121

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

10.92 USD

P/E Ratio

Dividend Yield

Financials CRDF

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Key Figures CRDF

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Current Year

+683 000 USD

Last Year

+488 000 USD

Current Quarter

+109 000 USD

Last Quarter

+151 000 USD

Current Year

+279 000 USD

Last Year

+488 000 USD

Current Quarter

+109 000 USD

Last Quarter

+55 000 USD
EBITDA -51 705 000 USD
Operating Margin TTM -13 194.50 %
Price to Earnings
Return On Assets TTM -41.00 %
PEG Ratio
Return On Equity TTM -74.15 %
Wall Street Target Price 10.92 USD
Revenue TTM 587 000 USD
Book Value 1.07 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY -46.80 %
Dividend Yield
Gross Profit TTM -38 734 000 USD
Earnings per share -0.93 USD
Diluted Eps TTM -0.93 USD
Most Recent Quarter I 2025
Quarterly Earnings Growth YOY
Profit Margin

Stock Valuation CRDF

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 273.08
Price Sales TTM 414.80
Enterprise Value EBITDA -3.66
Price Book MRQ 3.37

Technical Indicators CRDF

For 52 Weeks

2.01 USD 5.64 USD
50 Day MA 3.16 USD
Shares Short Prior Month 17 633 640
200 Day MA 3.33 USD
Short Ratio 17.21
Shares Short 17 289 872
Short Percent 26.68 %